Tempol

Phase 1Small molecule

AAdamis Pharmaceuticals Corporation

Tempol is one of 45 small molecule programs targeting Dermatitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DermatitisActive, not recruiting

COVID-19Active, not recruiting

DermatitisPhase 1

Active, not recruiting

COVID-19Phase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Bnt162b2

BioNTech

Preclinical

29 2

Tricor

JJagotec

Preclinical

1 3

Statin

Bristol-Myers Squibb

Preclinical

1 4

Glucocorticoid

AbbVie

Preclinical

1 5

Nadroparin

GSK

Preclinical

1 6

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 7

Selenium

SSWOG Cancer Research Network

Preclinical

1 8

Blood Taken

HHospices Civils de Lyon

Preclinical

1 9

MRNA COVID-19 Vaccine

Novartis

Preclinical

4 10

DAS181

AAnsun Biopharma, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2Recruiting

ESS

NCT06424756

Clinical

Trials by Indication[1]

Toxicities1 trial

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

Recruiting·MMatrix Biomed, Inc.·Phase 2·NCT03480971·120 enrolled

COVID-191 trial

Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

Terminated·AAdamis Pharmaceuticals Corporation·Phase 2/3·NCT04729595·248 enrolled

Dermatitis1 trial

Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01324141·6 enrolled

Metastatic Cancer1 trial

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

Available·MMatrix Biomed, Inc.··NCT05491928

ESS1 trial

Effects of an Antioxidant Supplement on Blood Vessel Health

Recruiting·UUniversity of Georgia·Phase 2·NCT06424756·60 enrolled

1 more indication

Local1 trial

The Effect of Antioxidants on Skin Blood Flow During Local Heating

Completed·TThe University of Texas at Arlington·Phase 1·NCT03680638·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Tempol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tempol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tempol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Adamis Pharmaceuticals Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAdamis Pharmaceuticals Corporation

Tempol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Toxicities1 trial

COVID-191 trial

Dermatitis1 trial

Metastatic Cancer1 trial

ESS1 trial

Local1 trial

References

Drug Info

Quick Facts

Related News